• Recombinant Annexin V for Apoptosis Detection

  2026-09-24

  Brumatti, Sheridan, and Martin describe a practical bacterial-expression and purification route for soluble recombinant annexin V, then explain how fluorescently labeled protein can detect phosphatidylserine exposure by flow cytometry or fluorescence microscopy. The work makes a widely used apoptosis probe more accessible while emphasizing that phosphatidylserine exposure is a membrane event that must be interpreted in biological context.

• GLT-1 Upregulation Limits TBI Injury via CB1-CREB

  2026-09-24

  A 2025 mouse study links post-traumatic increases in 2-arachidonoylglycerol to reduced astrocytic GLT-1 through CB1-CREB signaling, connecting endocannabinoid activity with impaired glutamate clearance. Its results identify GLT-1 regulation as a potential route to reduce neuronal apoptosis and cognitive deficits, while leaving important questions about timing, mechanism, and translation to human injury.

• PD 0332991: Practical CDK4/6 Workflows

  2026-09-23

  Use PD 0332991 (Palbociclib) HCl to test how CDK4/6-dependent Rb signaling controls proliferation and senescence in Rb-positive cancer models. This guide pairs a practical cell-cycle workflow with a CRISPR-screen finding that can help distinguish drug exposure from genuine resistance biology.

• Firefly Luciferase mRNA: Assay Design Guide

  2026-09-23

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a luminescent reporter: its cap, nucleotide chemistry, and poly(A) architecture shape assay interpretation. This guide connects transcript design with delivery stability, controls, and practical decisions for gene expression, viability, and in vivo imaging studies.

• Palbociclib in Patient-Derived Tumor Assays

  2026-09-22

  Palbociclib (PD0332991) enables a mechanistic readout of CDK4/6-dependent proliferation, from Rb phosphorylation and cell cycle G0/G1 arrest to later apoptosis. Combined with matched tumor–stroma assembloids, it can reveal why drug sensitivity changes when a realistic microenvironment is restored.

• Nimbolide–RNF114 Axis Drives PARP1 Trapping in BRCA Cancer

  2026-09-22

  Li and colleagues identified RNF114 as a PARylation-dependent E3 ubiquitin ligase that controls PARP1 removal from DNA lesions. Their work shows that nimbolide inhibits RNF114, increases PARP1 and repair-factor trapping, produces synthetic lethality in BRCA-mutated cancer, and can overcome resistance to conventional PARP inhibitors.

• Nilotinib in Collision-Aware Kinase Assays

  2026-09-21

  Nilotinib (AMN-107) is widely used to interrogate BCR-ABL, KIT, and PDGFR signaling. This article develops a collision-aware assay strategy that separates direct oncogenic kinase inhibition from ribosome-stress responses, improving interpretation in cancer research.

• Canagliflozin: A Mechanistic Assay Guide

  2026-09-21

  Explore Canagliflozin hemihydrate as an SGLT2 research compound and learn how negative evidence from a drug-sensitized yeast mTOR screen can improve assay interpretation, controls, and pathway claims.

• JZL184: Selective MAGL Inhibitor Research Guide

  2026-09-20

  JZL184 is a selective monoacylglycerol lipase inhibitor that increases 2-arachidonoylglycerol availability and enables controlled study of endocannabinoid signaling modulation. Evidence from neuronal and traumatic brain injury models supports its use for CB1 receptor mediated synaptic modulation, while also defining important limits for interpreting behavioral and GLT-1 results.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-19

  Brumatti, Sheridan, and Martin established a practical workflow for producing soluble, polyhistidine-tagged recombinant annexin V in Escherichia coli, followed by FITC conjugation and use in apoptosis assays. The study is valuable because it connects accessible protein production with phosphatidylserine detection by flow cytometry and fluorescence microscopy, while clarifying the membrane biology underlying the readout.

• 2-NBDG Glucose Uptake Assay Kit for HCC

  2026-09-18

  The 2-NBDG Glucose Uptake Assay Kit enables rapid, non-radioactive mapping of glucose transport in bulk cultures, organoids, and single cells. Its fluorescence-based workflow adds a practical metabolic layer to hepatocellular carcinoma studies investigating HNF4A-AS1, sorafenib response, and lipid-driven ferroptosis.

• 2-Thio-dCTP: DNA Assay Workflows

  2026-09-18

  Build more informative DNA polymerase and DNA–protein interaction assays with 2-Thio-dCTP, a sulfur-substituted cytidine triphosphate designed for controlled nucleotide incorporation. This guide connects practical DNA modification workflows with the SCP4–H3T3 chromosome-stability pathway while clearly separating established evidence from exploratory applications.

• BML-277: Chk2 Inhibition as a Causal Probe

  2026-09-17

  BML-277 is a potent Chk2 inhibitor for dissecting DNA damage signaling beyond simple kinase readouts. This article connects the nuclear cGAS–TRIM41–ORF2p discovery to assay design, causal inference, and carefully bounded applications in T-cell radioprotection and cancer research.

• BML-277 and the Chk2–cGAS Genome Integrity Axis

  2026-09-17

  A translational perspective on using BML-277 to dissect Chk2 signaling, nuclear cGAS biology, T-cell radioprotection, and genome stability while separating established evidence from testable hypotheses.

• LY2603618 Chk1 Inhibitor Workflow Guide

  2026-09-16

  Build reproducible DNA-damage and cell-cycle assays with LY2603618, a selective Chk1 inhibitor suited to replication-stress and chemotherapy-sensitization studies. This workflow connects practical dosing with redox and nucleotide-pool biomarkers that can explain why NSCLC models respond differently.

8113 records 1/541 page Next 12345 下5页 Last page